Table 1. Clinical manifestations of 78 patients with clinical isolations of carbapenem-resistant Enterobacteriacae that were acquired from community or healthcare setting.
| Variable | No. (%) of community–acquired (n = 23) | No. (%) of healthcare-acquired (n = 66) | P value |
|---|---|---|---|
| Age ≥ 65 | 20 (87.0) | 32 (58.2) | 0.028 |
| Male (%) | 9 (39.1) | 39 (70.9) | 0.018 |
| Pathogens | |||
| K. pneumoniae | 13 (56.5) | 29 (52.7) | 0.957 |
| E. cloacae | 5 (21.7) | 19 (34.5) | 0.396 |
| E. coli | 4 (17.4) | 7 (12.7) | 0.852 |
| P. mirabilis | 1 (4.3) | 0 (0.0) | 0.661 |
| Clinical significance | 0.154 | ||
| Colonization | 5 (21.7) | 4 (7.3) | |
| Infection | 18 (78.3) | 51 (92.7) | |
| Pneumonia | 7 (38.9) | 21 (41.2) | 0.914 |
| Urinary tract infection | 11 (61.1) | 13 (25.5) | 0.015 |
| Intra-abdominal infections | 0 (0.0) | 16 (31.4) | 0.017 |
| Central line-associated infection | 0 (0.0) | 1 (2.0) | 0.595 |
| Bacteremia | 0 (0.0) | 6 (10.9) | 0.237 |
| Underlying diseases/conditions | |||
| Cancer | 6 (26.1) | 28 (50.9) | 0.078 |
| Diabetes mellitus | 11 (47.1) | 17 (30.9) | 0.270 |
| Chronic kidney disease | 7 (30.4) | 10 (18.2) | 0.374 |
| Liver cirrhosis | 3 (13.0) | 7 (12.7) | 0.737 |
| Steroid use | 5 (21.7) | 15 (27.3) | 0.816 |
| Immunosuppressant use | 3 (13.0) | 20 (36.4) | 0.073 |
| Receive total parenteral nutrition | 0 (0.0) | 5 (9.1) | 0.323 |
| Intra-abdominal surgery | 0 (0.0) | 12 (21.8) | 0.037 |
| Procedure within 3 months | |||
| Esophagogastroduodenoscopy | 2 (8.7) | 19 (34.5) | 0.039 |
| Bronchoscopy | 2 (8.7) | 3 (5.5) | 0.985 |
| Colonoscopy | 0 (0.0) | 3 (5.5) | 0.614 |
| In-hospital mortality | 4 (17.4) | 10 (18.2) | 0.811 |